Superomniphobic flow controlled prosthetic heart valve

项目总结： 目前所有的人工心脏瓣膜都存在并发症。机械心脏瓣膜(HV)需要终生 抗凝治疗，尽管基于固定组织的生物瓣膜存在耐用性问题， 免疫原性和钙化问题。带涡流的超全向恐惧型双叶机械瓣膜 发电机(VG)技术有望消除抗凝治疗的需要。我们的实验室已经研制出一种 因此，带有VGS的双叶机械心脏瓣膜(BMHV)也显著改善了表面血液相容性 AS可消除湍流应力，从而降低血小板的活性。初步研究表明，这样的表面 与普通的热解碳叶相比，显著降低了血栓形成潜力。此外，我们已经 论证了制造BMHV并将其与VGS组装成植入型BMHV的可行性。 目前的R21研究旨在评估SO BMHV与VG作为当前心脏的潜在替代品的有效性 阀门技术通过微调材料成分和加工，满足耐用性和抗血栓形成的要求 对心脏瓣膜的要求。我们的中心假设是：有涡流发生流的超无所不在的BMHV 控制技术将在血流动力学性能、血液损伤和 血液与材料表面的相容性，同时表现出令人满意的耐用性。这在两个目标上得到了检验。目标1 用VG和BMHV量化SO的心脏瓣膜血流动力学性能以确定理想的SO VG 配置优越的血流动力学，最大限度地减少血液损伤。目标2侧重于阐明这些影响 小叶成分和加工对血液相容性的影响，同时优化强度和血液相容性 涂层的颜色。这项提议由拉克希米·普拉萨德·达西博士领导，他是一名训练有素的年轻研究员， 擅长心脏瓣膜工程和心血管生物力学，是几种心脏瓣膜的发明者 包括VGS和新型生物分子聚合物小叶在内的技术。多名PI是Kota博士，他是一位成熟的 超疏水材料专家；Popat博士，其专长在于生物兼容性和表面 纳米工程。如果拟议的工作证明了这一点，那么VG BMHV就会产生出色的血流动力学， 而且是耐用的，这笔R21赠款可能会导致机械HV和所有其他血液的突破性技术 接触装置(如人造心脏、左心室反搏装置等)几乎不需要或根本不需要抗凝。

Project Summary: All present day prosthetic heart valves suffer from complications. Mechanical heart valves (HVs) require life-long anti-coagulation therapy, while bioprosthetic heart valves based on fixed tissue are plagued with durability, immunogenic and calcification issues. Superomniphobic (SO) bileaflet mechanical heart valves with vortex generator (VG) technology promise to eliminate the need for anti-coagulation therapy. Our lab has developed a SO bileaflet mechanical heart valve (BMHV) with VGs that drastically improve surface hemocompatibility as well as eliminate turbulent stresses, thus reducing platelet activation. Preliminary work has shown that SO surfaces remarkably reduced thrombogenic potential relative to plain pyrolytic carbon leaflets. Further, we have already demonstrated the feasibility of manufacturing BMHVs and assembling them with VGs into an implantable BMHV. The present R21 study aims to gauge the efficacy of SO BMHV with VG as a potential alternative to current heart valve technology by fine tuning material composition and processing to meet the durability and antithrombogenic requirements for heart valves. Our central hypothesis is: superomniphobic BMHVs with vortex generator flow control technology will be superior to current BMHVs in terms of hemodynamic performance, blood damage, and blood-material surface compatibility while exhibiting satisfactory durability. This is tested in two aims. Aim 1 quantifies heart valve hemodynamic performance of SO with VG BMHVs to identify the ideal SO+VG configuration for superior hemodynamics and minimum blood damage. Aim 2 focuses on elucidating the effects of leaflet composition and processing on hemocompatibility while optimizing the strength and hemocompatibility of the coating. This proposal is led by Dr. Lakshmi Prasad Dasi, who is a well trained young investigator with expertise in heart valve engineering and cardiovascular biomechanics, and inventor of several heart valve technologies including VGs and novel biomolecule polymer leaflets. Multi-PIs are Dr. Kota, who is an established superhydrophobic materials expert; Dr. Popat whose expertise lies in bio-compatibility and surface nano-engineering. If the proposed work demonstrates that SO with VG BMHVs elicit excellent hemodynamics, and are durable, this R21 grant may lead to breakthrough technology for mechanical HVs and all other blood contacting devices (e.g. artificial hearts, LVADs etc.) that require little or no anticoagulation.